Evidence map›Paper›PMID 34660300›Full record

ArticleFrontiers in oncology2021

Expression Levels of Three Key Genes CCNB1, CDC20, and CENPF in HCC Are Associated With Antitumor Immunity.

Tengfei Si, Zhenlin Huang, Yuanhang Jiang, Abigail Walker-Jacobs, Shaqira Gill, Robert Hegarty, Mohammad Hamza, Shirin Elizabeth Khorsandi, Wayel Jassem, Nigel Heaton and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Tengfei SiInstitute of Liver Studies, King's College Hospital, Department of Inflammation Biology, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom.
Zhenlin HuangThe Ministry of Education (MOE) Key Laboratory for Standardization of Chinese Medicine, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yuanhang JiangInstitute of Liver Studies, King's College Hospital, Department of Inflammation Biology, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom.
Abigail Walker-JacobsInstitute of Liver Studies, King's College Hospital, Department of Inflammation Biology, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom.
Shaqira GillInstitute of Liver Studies, King's College Hospital, Department of Inflammation Biology, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom.
Robert HegartyPediatric Liver, GI and Nutrition Centre, King's College Hospital, London, United Kingdom.
Mohammad HamzaInstitute of Liver Studies, King's College Hospital, Department of Inflammation Biology, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom.
Shirin Elizabeth KhorsandiInstitute of Liver Studies, King's College Hospital, Department of Inflammation Biology, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom.
Wayel JassemInstitute of Liver Studies, King's College Hospital, Department of Inflammation Biology, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom.
Nigel HeatonInstitute of Liver Studies, King's College Hospital, Department of Inflammation Biology, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom.
Yun MaInstitute of Liver Studies, King's College Hospital, Department of Inflammation Biology, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom.
King's College London · GBKing's College Hospital · GBShanghai University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHepatocellular carcinoma (HCC) is the most common primary liver cancer with a low 5-year survival rate. The heterogeneity of HCC makes monotherapy unlikely. The development of diagnostic programs and new treatments targeting common genetic events in the carcinogenic process are providing further insights into the management of HCC. The aim of this study was firstly to validate key genes that are involved in promoting HCC development and as biomarkers for early diagnosis and, secondly, to define their links with antitumor immunity including inhibitory checkpoints.

methodsMultiple databases including Gene Expression Omnibus (GEO), Gene Expression Profiling Interactive Analysis (GEPIA), Kaplan-Meier Plotter, UALCAN, and Oncomine were used for target gene screening and establishment of a co-expression network. Clinical data and RNAseq of 367 HCC patients were downloaded from the Cancer Genome Atlas (TCGA) database. The diagnostic and prognostic value of screened genes were tested by receiver operating characteristic (ROC) curve and correlation analysis. The links with the key genes in HCC and antitumor immunity were defined using both blood and liver tissue collected prospectively from HCC patients in our center.

resultsUpregulation of CCNB1, CDC20, and CENPF was commonly observed in HCC and are involved in the p53 signal pathway. The hepatic mRNA expression levels of these three genes were strongly associated with patients' prognosis and expressed high value of area under the ROC curve (AUC). Further analysis revealed that these three genes were positively correlated with the gene expression levels of IFN-γ, TNF-α, and IL-17 in peripheral blood. In addition, the expression of CENPF showed positive correlation with the percentage of CD8

conclusionThe upregulation of CCNB1, CDC20, and CENPF genes was a common event in hepatocarcinogenesis. Expression levels of CCNB1, CDC20, and CENPF showed potential for early diagnosis and prediction of prognosis in HCC patients. There is a close association between three genes and Th1/Th17 cytokines as well as the count of CD4

Indexed as

antitumor immunityHCChepatocarcinogenesisinhibitory checkpointprognosis

Identifiers

PMID34660300
PMCPMC8515852
OpenAlexW3203234787

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.